Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease

Monia Marchetti, Nicola L. Liberato, Antonio Di Sabatino, Gino R. Corazza

Research output: Contribution to journalArticle

Abstract

Background: Top-down (TD) strategy with frontline infliximab proved to be more effective than the traditional step-up (SU) approach in newly diagnosed luminal moderate-to-severe CD patients. However, the considerable cost of infliximab calls its universal use as frontline treatment into question. The aim of this study is to evaluate the cost-effectiveness of the TD approach using a Markov decision model. Methods: Four states were modelled, namely step 1, step 2, step 3 and death. The first three steps were in TD infliximab induction plus azathioprine, infliximab rechallenge plus azathioprine and steroids plus azathioprine, and in SU steroid induction, azathioprine plus steroid rechallenge and infliximab plus azathioprine. Each health state lasted 1 month. The time horizon of the model was 5 years. Transition probabilities and quality of life were estimated from a randomised trial. First- and second-order sensitivity analyses were done to test the robustness of the results. Results: At baseline analysis, TD improved quality-adjusted life expectancy from 3.76 to 3.90 quality-adjusted life years (QALYs), that is, 0.14 QALYs, while allowing a saving of €773, proving dominant when compared to SU. TD was cost-saving in 66 % of the Monte Carlo simulations and cost

Original languageEnglish
Pages (from-to)853-861
Number of pages9
JournalEuropean Journal of Health Economics
Volume14
Issue number6
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Cost-effectiveness
  • Crohn's disease
  • Infliximab
  • Step-up
  • Top-down

ASJC Scopus subject areas

  • Health Policy
  • Economics, Econometrics and Finance (miscellaneous)

Fingerprint Dive into the research topics of 'Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease'. Together they form a unique fingerprint.

  • Cite this